Adenoviral vectors for mutants of human interleukin 6 (hIL-6) with hIL-6 antagonist activity, pharmaceutical compositions therewith and their uses
AssigneesInstituto di Ricerche di Biologgia Molecolare, Centre National De La Recherche Scientifique
InventorsGennaro Ciliberto, Isabella Saggio, Rocco Savino, Michel Perricaudet
Life of this patent
Estimating the term…
Abstract
The subject matter of the present invention are recombinant defective adenoviruses comprising a heterologous DNA sequence coding for a mutein having the activity of human Interleukin 6 (hIL-6) antagonists or superantagonist. Moreover, the invention refers to therapeutical uses thereof, in particular for preparing pharmaceutical compositions for treating and/or preventing pathologies caused by hIL-6 overproduction.
Claims8
A method for inhibiting the activity of IL-6 in a population of human cells in vitro comprising introducing into said human cells a recombinant defective adenovirus, comprising DNA encoding mutant human interleukin 6 (hIL-6);
- said mutant hIL-6 comprising amino acid substitutions Tyr31 Asp, Gly35 Phe, Ser118Arg, Val121Asp, Gln175Ile, Ser176Arg, and Gln183Ala.
A method for inhibiting the activity of IL-6 in a population of human cells in vitro comprising introducing into said human cells a recombinant defective adenovirus, comprising DNA encoding mutant human interleukin 6 (hIL);
- said mutant hIL-6 comprising amino acid substitutions Tyr31Asp, Gly35Phe, Leu57Asp, Glu59Phe, Asn60Trp, Gln75Tyr, Ser76Lys, Ser118Arg, Val121Asp, Gln175Ile, Ser176Arg, and Gln183Ala.
Dependencies are inferred from the claim text.